This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: The Innovative Contributions of Travis Mathew Stams
Introduction
Travis Mathew Stams is a notable inventor based in Stow, MA (US). He has made significant contributions to the field of pharmacology through his innovative research and development of compounds that target various health conditions. His work is particularly focused on the inhibition of PTPases, which play a crucial role in several metabolic disorders.
Latest Patents
Stams holds a patent for "5-substituted 1,1-dioxo-1,2,5-thiadiazolidin-3-one derivatives." This patent describes compounds that serve as pharmacological agents, specifically inhibitors of PTP-1B and TC PTP. These compounds may be utilized in the treatment of conditions associated with PTPase activity, including insulin resistance related to obesity, diabetes mellitus, and hypertension. Furthermore, the compounds have potential applications in treating various diseases, such as cancer, osteoporosis, and neurodegenerative disorders.
Career Highlights
Travis Mathew Stams is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other experts in the field, enhancing the impact of his research on public health.
Collaborations
Stams has worked alongside notable colleagues, including John William Davies and Charles Francis Jewell, Jr. These collaborations have contributed to the advancement of innovative solutions in pharmacology and related fields.
Conclusion
Travis Mathew Stams exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations continue to pave the way for advancements in the treatment of various health conditions.